梅花生物完成4.92亿股份回购 半年净利增19.96%加速全球化

Core Viewpoint - Meihua Biological has successfully completed its share repurchase plan, signaling strong financial health and stability in its operations, while also focusing on expanding its global presence in the amino acid industry [1][4]. Group 1: Share Repurchase and Financial Performance - The company repurchased 48.5471 million shares, accounting for 1.70% of its total share capital, at a price range of 9.10 to 10.97 yuan per share, totaling 492 million yuan [2][3]. - The repurchased shares will be canceled, reducing the total share capital from 2.853 billion shares to 2.804 billion shares, and increasing the shareholding ratio of major shareholders from 33.34% to 33.92% [2][3]. - In the first half of 2025, the company reported a net profit of 1.768 billion yuan, a year-on-year increase of 19.96%, despite a slight decline in revenue [6]. Group 2: Business Strategy and Market Position - Meihua Biological has focused on its core business of amino acids, enhancing its competitive edge through international expansion and refined operations [1][5]. - The company has maintained a stable profit distribution policy, with cumulative cash dividends exceeding 12 billion yuan since its restructuring in 2010, and a record dividend payout of 1.699 billion yuan for 2024 [3][4]. - The company has a diversified product matrix, leading in the production of lysine and threonine globally, and ranking second in MSG production [5]. Group 3: Research and Development - Meihua Biological has increased its R&D investment, with total R&D expenses reaching 897 million yuan over two and a half years, reflecting a commitment to maintaining its technological leadership in the industry [7]. - The company has accelerated its international strategy, completing a cross-border acquisition that enhances its product offerings and strengthens its global supply chain position [7].